2015 BioChallenge Competition Finalists Announced

On November 18 at the Joy Theater, four life sciences startups will pitch to a panel of investors and industry expert judges for a $25,000 cash prize. This year’s finalists are:

‪BioAesthetics is improving reconstruction options for breast cancer patients after they undergo mastectomies. These women have several options for nipple-areolar complex (NAC) reconstruction, including surgery, tattoos, and prosthetics, but the success of these procedures is variable and some are not permanent. BioAesthetics has developed a graft that would instead allow the patient’s body to regenerate a permanent NAC.  

Flux Diagnostics
Flux aims to revolutionize rapid diagnosis of various diseases without the need for extensive training or complex equipment. The startup is developing fast, low cost in-vitro diagnostic tests with a unique detection system and multiplex technology. Flux is initially targeting dengue fever, a mosquito-borne virus that infects an estimated 390 million people worldwide each year.

InnoGenomics Technologies
InnoGenomics is dedicated to the development of innovative genetic testing solutions that solve crimes and save lives. Their patented technology enables forensic scientists to unlock answers from the most challenging DNA evidence, and it can be used to detect and monitor cancer through a minimally invasive blood test.

Zenopharm, a Xavier University spinout, is developing a drug candidate to treat and prevent recurrence of breast cancer. This is more effective in preventing recurrence at a fraction of the dosage required for the current standard-of-care drug tamoxifen. This will reduce adverse side effects, increase patient treatment adherence, and reduce the risk of breast cancer recurrence.

Get more info about the live pitch finals and RSVP here!

UK Expert to Discuss Bringing New Products to the British Healthcare System

Join us October 22 for a networking hour and seminar on how companies and universities access regulatory bodies in the United Kingdom to bring innovative new products and services into the National Health Service. This is the largest single-payer healthcare system in the world — don’t miss this seminar to ensure you know how to bring your new technology to patients and clinicians in a major global market.

Our speaker, Dr. Andrew Rose, works in Liverpool at the North West Coast AHSN to develop the Life Sciences and Health sectors across the region by supporting collaborations/networking, business growth, and wider strategic initiatives, particularly those focused on research and innovation.

Learn more and RSVP here.

North West Coast Academic Health Science Network
The North West Coast AHSN is a network of NHS organisations, universities and businesses to identify areas of need, speed up the adoption of innovation, identify and enable research, and create wealth, with consequent benefits for the health and wealth of individuals, communities, regions and the nation. The NWCAHSN covers a population of 4 million residents and is delivering a step change in the way the NHS identifies, develops and adopts new innovative products and services.

The NWCAHSN is one of 9 HSN’s in England which have “innovation scouts” based in 25 NHS Trusts who are tasked with bringing in new treatments, technologies, etc. They are the bridge between companies, hospitals, Universities and regulatory bodies.